WuXi Biologics and Boostimmune Sign an Agreement for Exclusive Research and Discovery Services

India Pharma Outlook Team | Wednesday, 16 August 2023

 India Pharma Outlook Team

WuXi Biologics (WuXi Bio), a leading global CRDMO, and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating the tumour immune microenvironment and ADCs to novel targets, announced the signing of a Memorandum of Understanding (MoU) for Boostimmune's pipeline research and discovery services. Boostimmune will have access to WuXi Biologics' integrated discovery services and substantial expertise in antibody discovery, lead optimisation, in vitro screening and characterisation, and in vivo studies as part of the agreement.

WuXi Biologics will be Boostimmune's exclusive service partner in the development of several modality candidates, including monoclonal antibodies, bispecific antibodies, and recombinant proteins. "Collaborating with WuXi Biologics - and accessing their comprehensive antibody generation technology platform - offers an opportunity to discover novel biological candidates and explore the science of complex proteins," said Dr. Gwanghee Lee, co-founder and CEO of Boostimmune. We are excited to collaborate with WuXi Biologics to develop a compelling pipeline with the potential to significantly enhance the lives of patients." Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are very pleased to partner with Boostimmune to advance their innovative pipeline.

The biotech industry in South Korea is flourishing, and there is increasing demand for end-to-end discovery and development services. WuXi Biologics is proud to support our global and Asia partners in bringing innovative biologics solutions to market for patients around the world.” Boostimmune is a biotech business that is developing novel, first-in-class antibody-based therapeutics to meet unmet oncology needs. Its pipeline studies include bare monoclonal antibodies that modify the cancer immune milieu, ADCs to novel targets with potential patient selection biomarkers, and an ISAC (Immune Stimulator Antibody Conjugate) that targets immunosuppressive myeloid cells directly. WuXi Biologics is a major global contract research, development, and manufacturing organisation (CRDMO) that provides end-to-end solutions for partners to find, develop, and manufacture biologics from idea to commercialization for the benefit of patients worldwide.

© 2024 India Pharma Outlook. All Rights Reserved.